The cost-effectiveness of PCSK9 inhibitors - The Australian healthcare perspective

This study aimed to determine the cost-effectiveness of PCSK9i compared to placebo in the prevention of atherosclerotic cardiovascular disease (CVD).

Source: International Journal of Cardiology - April 25, 2018 Category: Cardiology Authors: Radya Kumar, Andrew Tonkin, Danny Liew, Ella Zomer Source Type: research